Drug Trial Radar · NCT07025915
A Phase 1 Mass Balance Study of [¹⁴C]SSS17 in Healthy Chinese Males
Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
6
Planned (sponsor's estimate)
Start
Jun 2025
Primary completion
Jul 2025
Study completion Jul 2025
Sponsor
- Lead sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Jun 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to evaluate the absorption, metabolism, and excretion of a single oral dose of \[¹⁴C\]SSS17 in healthy adult Chinese male subjects, elucidating its overall pharmacokinetic profile in humans to provide essential information for its rational clinical use.
Conditions
- Healthy Subjects (HS)
Interventions
[14C]SSS17Drug
single oral dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative excretion rate of radioactivity in excreta (urine, feces) and total radioactivity (urine and feces)Time frame: up to Day 22
- CmaxTime frame: up to day22
- TmaxTime frame: up to Day22
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.